Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: Comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

Journal of Lipid Research

Volumn 41, Issue 7, 2000, Pages 1136-1144

  Hiyoshi, Hironobu ^a   Yanagimachi, Mamoru ^a   Ito, Masashi ^a   Ohtsuka, Issei ^a   Yoshida, Ichiro ^a   Saeki, Takao ^a   Tanaka, Hiroshi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Cholesterol biosynthesis; Cholesterol lowering; Enzyme inhibition; ER 97856; HMG CoA reductase; Rhesus monkeys; Squalene synthase

Indexed keywords

5 [N [2 BUTENYL 3 (2 METHOXYPHENYL)] N METHYLAMINO] 1,1 PENTHYLIDINEBIS(PHOSPHONIC ACID)TRISODIUM; ATORVASTATIN; CHOLESTEROL; DEXAMETHASONE; ER 27856; ER 28448; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PRAVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RHESUS MONKEY; STRUCTURE ANALYSIS;

ALANINE TRANSAMINASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MACACA MULATTA; MALE; MICROSOMES, LIVER; PRODRUGS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033942443     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Lipid Research Clinics. 1984. Lipid Research Clinics Program. J. Am. Med. Assoc. 252: 2545-2548.
2. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-430.
3. Brown, A. S., R. G. Bakker-Arkema, L. Yellen, R. W. Henley, Jr., R. Guthrie, C. F Campbell, M. Koren, W. Woo, R. McLain, and D. M. Black. 1998. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol. 32: 665-672.
4. McClellan, K. J., L. R. Wiseman, and D. McTavish. 1998. Cerivastatin. Drugs. 55: 415-422.
5. Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, and C. J. Packard. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333: 1301-1307.
6. Scandinavian Simvastatin Survival Study Group. 1994. Randotnised trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-1389.
7. Tobert, J. A. 1987. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation. 76: 534-538.
8. Hsu, I., S. A. Spinler, and N. E. Johnson. 1995. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann. Pharmacother. 29: 743-759.
9. Kornbrust, D. J., J. S. MacDonald, C. P. Peter, D. M. Duchai, R. J. Stubbs, J. I. Germershausen, and A. W. Alberts. 1989. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits, J. Pharmacol. Exp. Ther. 248: 498-505.
10. Satoh, K., A. Yamato, T. Nakai, K. Hoshi, and K. Ichihara. 1995. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br. J. Pharmacol. 116: 1894-1898.
11. Ichihara, K., K. Satoh, and V. Abiko. 1993. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J. Cardiovasc. Pharmacol. 22: 852-856.
12. Burton, P. M., D. C. Swinney, R. Heller, B. Dunlap, M. Chiou, E. Malonzo, J. Haller, K. A. Walker, A. Salari, S. Murakami, G. Mendizabal, and L. Tokes. 1995. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biorhem. Pharmacol. 50: 529-544.
13. Morand, O. H., J. D. Aebi, H. Dehmlow, Y. H. Ji, N. Gains, H. Lengsfeld, and J. Himber. 1997. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J. Lipid Res. 38: 373-390.
14. Biller, S. A., C. Forster, E. M. Gordon, T. Harrity, L. C. Rich, J. Marretta, and C. P. Ciosek, Jr. 1991. Isoprenyl phosphinylformates: new inhibitors of squalene synthetase. J. Med. Chem. 34: 1912-1914.
15. Ciosek, C. P., Jr., D. R. Magnin, T. W. Harrity, J. V. Logan, J. K. Dickson, Jr., E. M. Gordon, K. A. Hamilton, K. G. Jolibois, L. K. Kunselman, R. M. Lawrence, K. A. Mookhtiar, L. C. Rich, D. A. Slusarchyk, R. B. Sulsky, and S. A. Biller. 1993. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268: 24832-24837.
16. Dickson, J. K., Jr., S. A. Biller, D. R. Magnin, E. W. Petrillo, Jr., J. W. Hillyer, D. G. Hsieh, S. J. Lan, J. K. Rinehart, R. E. Gregg, T. W. Harrity, K. G. Jolibois, S. S. Kalinowski, L. K. Kunselman, K. A. Mookhtiar, and G. P. Ciosek, Jr. 1996. Orally active SQS inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. J. Med. Chem. 39: 661-664.
17. Magnin, D. R., S. A. Biller, Y. Chen, J. K. Dickson, Jr., O. M. Fryszman, R. M. Lawrence, J. V. Logan, E. S. Sieber-McMaster, R. B. Sulsky, S. C. Traeger, D. C. Hsieh, S. J. Lan, J. K. Rinehart, T. W. Harrity, K. G. Jolibois, L. K. Kunselman, L. G. Rich, D. A. Slusarchyk, and C. P. Ciosek, Jr. 1996. alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J. Med. Chem. 39: 657-660.
18. Amin, D., R. Z. Rutledge, S. N. Needle, H. F. Galczenski, K. Neuenschwander, A. C. Scotese, M. P. Maguire, R. C. Bush, D. J. Hele, G. E. Bilder, and M. H. Perrone. 1997. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. 281: 746-752.
19. Bergstrom, J. D., M. M. Kurtz, D. J. Rew, A. M. Amend, J. D. Karkas, R. G. Bostedor, V. S. Bansal, G. Dufresne, F. L. VanMiddlesworth, O. D. Hensens, J. M. Liesch, D. L. Zink, K. E. Wilson, J. Onishi, J. A. Milligan, G. Bills, L. Kaplan, M. Nallin Omstead, R. G. Jenkins, L. Huang, M. S. Meinz, L. Quinn, R. W. Burg, Y. L. Kong, S. Mochales, M. Mojena, I. Martin, F. Pelaez, M. T. Diez, and A. W. Alberts. 1993. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA. 90: 80-84.
20. Procopiou, P. A., E. J. Bailey, M. J. Bamford, A. P. Craven, B. W. Dymock, J. G. Houston, J. L. Hutson, B. E. Kirk, A. D. McCarthy, M. Sareen, J. J. Scicinski, P. J. Sharratt, M. A. Snowden, N. S. Watson, and R. J. Williams. 1994. The squalestatins: novel inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of Cl-modified analogues. J. Med. Chem. 37: 3274-3281.
21. Chan, C., D. Andreotti, B. Cox, B. W. Dymock, J. L. Hutson, S. E. Keeling, A. D. McCarthy, P. A. Procopiou, B. C. Ross, M. Sareen, J. J. Scicinski, P. J. Sharratt, M. A. Snowden, and N. S. Watson. 1996. The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors. J. Med. Chem. 39: 207-216.
22. Procopiou, P. A., B. Cox, B. E. Kirk, M. G. Lester, A. D. McCarthy, M. Sareen, P. J. Sharratt, M. A. Snowden, S. J. Spooner, N. S. Watson, and J. Widdowson. 1996. The squalestatins: inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C3-modified analogues. J. Med. Chem. 39: 1413-1422.
23. Baxter, A., B. J. Fitzgerald, J. L. Hutson, A. D. McCarthy, J. M. Motteram, B. C. Ross, M. Sapra, M. A. Snowden, N. S. Watson, R. J. Williams, and G. Wright. 1992. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem. 267: 11705-11708.
24. Tanimoto, T., K. Hamano, K Onodera, T. Osoya, M. Kakusaka, T. Hirayama, Y. Shimada, T. Koga, and Y. Tsujita. 1997. Biological activities of novel zaragozic acids, the potent inhibitors of squalene synthase, produced by the fungus, Mollisia sp. SANK 10294. J. Antibiol. (Tokyo). 50: 390-394.
25. Agnew, W. S. 1985. Squalene synthetase. Methods Enzimol. 110: 359-373.
26. Brower, P. L., D. E. Butler, C. F. Deering, T. V. Le, A. Millar, T. N. Nanninga, and B. D. Roth. 1992. The synthesis of (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33: 2279-2282.
27. Baumann, K. L., D. E. Butler, C. F. Deering, K. E. Mennen, A. Millar, T. N. Nanninga, C. W. Palmer, and B. D. Roth. 1992. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33: 2283-2284.
28. Ness, G. C., C. E. Sample, M. Smith, L. C. Pendleton, and D. C. Eichler. 1986. Characteristics of rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Biochem. J. 233: 167-172.
29. Brown, M.S., J. L. Goldstein, and J. M. Dietschy. 1979. Active and inactive forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states. J. Biol. Chem. 254: 5144-5149.
30. Cohen, L. H., A. M. Griffioen, R. J. Wanders, C. W. Van Roermund, C. M. Huysmans, and H. M. Princen. 1986. Regulation of squalene synthetase activity in rat liver: elevation by cholestyramine, but no diurnal variation. Biochem. Biophys. Res. Commun. 138: 335-341.
31. Moldeus, P., J. Hogberg, and S. Orrenius. 1978. Isolation and use of liver cells. Methods Enzymol. 52: 60-71.
32. Horie, M., Y. Tsuchiya, M. Hayashi, Y. Iida, Y. Iwasawa, Y. Nagata, Y. Sawasaki, H. Fukuzumi, K. Kitani, and T. Kamei. 1990. NB-598: a potent competitive inhibitor of squalene epoxidase. J. Biol. Chem. 265: 18075-18078.
33. Stephan, Z. F., and E. C. Yurachek. 1993. Rapid fluorometric assay of LDL-R activity by Dil-labeled LDL. J. Lipid Res. 34: 325-330.
34. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 265: 265-275.
35. Bundgaard, H. 1991. Novel chemical approaches in prodrug design. Drugs Future. 16: 443-458.
36. Chapman, M. J., and S. Goldstein. 1976. Comparison of the serum low density lipoprotein and of its apoprotein in the pig, rhesus monkey and baboon with that in man. Atherosclerosis. 25: 267-291.
37. Brown, M. S., and J. L. Goldstein. 1999. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA. 96: 11041-11048.
38. Jones, P., S. Kafonek, I. Laurora, and D. Hunninghake. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am. J. Cardiol. 81: 582-587.
39. Edwards, P. A., S. F. Lan, R. D. Tanaka, and A. M. Fogelman. 1983. Mevalonolactone inhibits the rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat hepatocytes. J. Biol. Chem. 258: 7272-7275.
40. Nakanishi, M., J. L. Goldstein, and M. S. Brown. 1988. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J. Biol. Chem. 263: 8929-8937.
41. Roitelman, J., and R. D. Simoni. 1992. Distinct sterol and non-sterol signals for the regulated degradation of 3-hydroxy-3-methylglutaryl-CoA reductase. J. Biol. Chem. 267: 25264-25273.
42. Bradfute, D. L., and R. D. Simoni. 1994. Non-sterol compounds that regulate cholesterogenesis. Analogues of FPP reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J. Biol. Chem. 269: 6645-6650.
43. Correll, C. C., L. Ng, and P. A. Edwards. 1994. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269: 17390-17393.
44. Meigs, T. E., D. S. Roseman, and R. D. Simoni. 1996. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the non-sterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271: 7916-7922.
45. Correll, C. C., and P. A. Edwards. 1994. Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro. J. Biol. Chem. 269: 633-638.
46. Peffley, D. M., and A. K. Gayen. 1997. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Arch. Biochem. Biophys. 337: 251-260.
47. Meigs, T. E., and R. D. Simoni. 1997. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys. 345: 1-9.
48. Petras, S. F., S. Lindsey, and H. J. Harwood, Jr. 1999. HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived non-sterol regulator production in cultured IM-9 cells. J. Lipid Res. 40: 24-38.
49. Gardner, R. G., and R. Y. Hampton. 1999. A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes. J. Biol. Chem. 274: 31671-31678.